This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (149)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Journalology/ Peer Review/ Authorship  • Alert me on articles by topic

John P. A. Ioannidis, MD

JAMA. 1998;279:281-286.

Context.— Medical evidence may be biased over time if completion and publication of randomized efficacy trials are delayed when results are not statistically significant.

Objective.— To evaluate whether the time to completion and the time to publication of randomized phase 2 and phase 3 trials are affected by the statistical significance of results and to describe the natural history of such trials.

Design.— Prospective cohort of randomized efficacy trials conducted by 2 trialist groups from 1986 to 1996.

Setting.— Multicenter trial groups in human immunodeficiency virus infection sponsored by the National Institutes of Health.

Patients.— A total of 109 efficacy trials (total enrollment, 43708 patients).

Main Outcome Measures.— Time from start of enrollment to completion of follow-up and time from completion of follow-up to peer-reviewed publication assessed with survival analysis.

Results.— The median time from start of enrollment to publication was 5.5 years and was substantially longer for negative trials than for results favoring an experimental arm (6.5 vs 4.3 years, respectively; P<.001; hazard ratio for time to publication for positive vs negative trials, 3.7; 95% confidence interval [CI], 1.8-7.7). This difference was mostly attributable to differences in the time from completion to publication (median, 3.0 vs 1.7 years for negative vs positive trials; P<.001). On average, trials with significant results favoring any arm completed follow-up slightly earlier than trials with nonsignificant results (median, 2.3 vs 2.5 years; P=.045), but long-protracted trials often had low event rates and failed to reach statistical significance, while trials that were terminated early had significant results. Positive trials were submitted for publication significantly more rapidly after completion than were negative trials (median, 1.0 vs 1.6 years; P=.001) and were published more rapidly after submission (median, 0.8 vs 1.1 years; P=.04).

Conclusion.— Among randomized efficacy trials, there is a time lag in the publication of negative findings that occurs mostly after the completion of the trial follow-up.

From the HIV Research Branch, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

RELATED LETTER

Registering Clinical Trials—Reply
Kay Dickersin and Drummond Rennie
JAMA. 2003;290(19):2546.
EXTRACT | FULL TEXT  

RELATED ARTICLE

The Randomized Controlled Trial Gets a Middle-aged Checkup
Alejandro R. Jadad and Drummond Rennie
JAMA. 1998;279(4):319-320.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

"Intention to Analyze" in Pharmacogenomics Studies
Munafo et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:740-741.
FULL TEXT  

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy
Turner et al.
NEJM 2008;358:252-260.
ABSTRACT | FULL TEXT  

An exploratory test for an excess of significant findings
Ioannidis and Trikalinos
Clin Trials 2007;4:245-253.
ABSTRACT  

The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey
Ioannidis and Trikalinos
CMAJ 2007;176:1091-1096.
ABSTRACT | FULL TEXT  

Statistical and Clinical Interpretation of Research Results
Allison
J. Am. Podiatr. Med. Assoc. 2007;97:165-170.
ABSTRACT | FULL TEXT  

Clinical trial registration at Tobacco Control
Bero
Tobacco Control 2006;15:417-418.
FULL TEXT  

Evidence of publication bias in reporting acute stroke clinical trials.
Liebeskind et al.
Neurology 2006;67:973-979.
ABSTRACT | FULL TEXT  

Peer-reviewed publication of clinical trials completed for pediatric exclusivity.
Benjamin et al.
JAMA 2006;296:1266-1273.
ABSTRACT | FULL TEXT  

Commentary: Grading the credibility of molecular evidence for complex diseases
Ioannidis
Int J Epidemiol 2006;35:572-578.
FULL TEXT  

Transition From Meeting Abstract to Full-length Journal Article for Randomized Controlled Trials
Toma et al.
JAMA 2006;295:1281-1287.
ABSTRACT | FULL TEXT  

Bias in Clinical Intervention Research
Gluud
Am J Epidemiol 2006;163:493-501.
ABSTRACT | FULL TEXT  

Acetylcysteine in the Prevention of Contrast-Induced Nephropathy: A Case Study of the Pitfalls in the Evolution of Evidence
Bagshaw et al.
Arch Intern Med 2006;166:161-166.
ABSTRACT | FULL TEXT  

A Network of Investigator Networks in Human Genome Epidemiology
Ioannidis et al.
Am J Epidemiol 2005;162:302-304.
ABSTRACT | FULL TEXT  

Contradicted and Initially Stronger Effects in Highly Cited Clinical Research
Ioannidis
JAMA 2005;294:218-228.
ABSTRACT | FULL TEXT  

Fate of biomedical research protocols and publication bias in France: retrospective cohort study
Decullier et al.
BMJ 2005;331:19.
ABSTRACT | FULL TEXT  

CTLA-4 Gene Polymorphisms and Susceptibility to Type 1 Diabetes Mellitus: A HuGE Review and Meta-Analysis
Kavvoura and Ioannidis
Am J Epidemiol 2005;162:3-16.
ABSTRACT | FULL TEXT  

Challenges in Systematic Reviews of Therapeutic Devices and Procedures
Hartling et al.
ANN INTERN MED 2005;142:1100-1111.
ABSTRACT | FULL TEXT  

Submission to multiple journals: a method of reducing time to publication?
Torgerson et al.
BMJ 2005;330:305-307.
FULL TEXT  

Randomized clinical trials: What gets published, and when?
Hirsch
CMAJ 2004;170:481-483.
FULL TEXT  

Registering Clinical Trials--Reply
Dickersin and Rennie
JAMA 2003;290:2546-2546.
FULL TEXT  

Factors Associated With Failure to Publish Large Randomized Trials Presented at an Oncology Meeting
Krzyzanowska et al.
JAMA 2003;290:495-501.
ABSTRACT | FULL TEXT  

Registering Clinical Trials
Dickersin and Rennie
JAMA 2003;290:516-523.
ABSTRACT | FULL TEXT  

Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin et al.
BMJ 2003;326:1167-1170.
ABSTRACT | FULL TEXT  

Association of the CYP17 Gene Polymorphism with the Risk of Prostate Cancer: A Meta-Analysis
Ntais et al.
Cancer Epidemiol. Biomarkers Prev. 2003;12:120-126.
ABSTRACT | FULL TEXT  

Commentary: Meta-analysis of Individual Participants' Data in Genetic Epidemiology
Ioannidis et al.
Am J Epidemiol 2002;156:204-210.
FULL TEXT  

Physicians' interpretation of "class effects": A need for thoughtful re-evaluation
Kennedy and Rosenson
J Am Coll Cardiol 2002;40:19-26.
ABSTRACT | FULL TEXT  

Long-Term Outcome of Fasciotomy with Partial Fasciectomy for Chronic Exertional Compartment Syndrome of the Lower Leg
Slimmon et al.
Am J Sports Med 2002;30:581-588.
ABSTRACT | FULL TEXT  

Correlation of Quality Measures With Estimates of Treatment Effect in Meta-analyses of Randomized Controlled Trials
Balk et al.
JAMA 2002;287:2973-2982.
ABSTRACT | FULL TEXT  

Relation between burden of disease and randomised evidence in sub-Saharan Africa: survey of research
Isaakidis et al.
BMJ 2002;324:702-702.
ABSTRACT | FULL TEXT  

Hidden Barriers to Improvement in the Quality of Care
McNeil
NEJM 2001;345:1612-1620.
FULL TEXT  

Effect of Early Patient Enrollment on the Time to Completion and Publication of Randomized Controlled Trials
Haidich and Ioannidis
Am J Epidemiol 2001;154:873-880.
ABSTRACT | FULL TEXT  

Comparison of Evidence of Treatment Effects in Randomized and Nonrandomized Studies
Ioannidis et al.
JAMA 2001;286:821-830.
ABSTRACT | FULL TEXT  

Prepublication Release of Medical Research
Fontanarosa and Flanagin
JAMA 2000;284:2927-2929.
FULL TEXT  

Observational Studies and Randomized Trials
Kunz et al.
NEJM 2000;343:1194-1197.
FULL TEXT  

Electronic Trial Banks: A Complementary Method for Reporting Randomized Trials
Sim et al.
Med Decis Making 2000;20:440-450.
ABSTRACT  

Open and Arthroscopic Patellar Tenotomy for Chronic Patellar Tendinopathy: A Retrospective Outcome Study
Coleman et al.
Am J Sports Med 2000;28:183-190.
ABSTRACT | FULL TEXT  

Lack of Efficacy of Transdermal Nicotine in Smoking Cessation
Joseph and Antonuccio
NEJM 1999;341:1157-1158.
FULL TEXT  

JAMA-EXPRESS: Rapid Peer Review and Publication
Winker and Fontanarosa
JAMA 1999;281:1754-1755.
FULL TEXT  

The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials
Kunz and Oxman
BMJ 1998;317:1185-1190.
ABSTRACT | FULL TEXT  

Publication Bias and Research on Passive Smoking: Comparison of Published and Unpublished Studies
Misakian and Bero
JAMA 1998;280:250-253.
ABSTRACT | FULL TEXT  

Time Lag Bias in Publishing Clinical Trials
Clarke et al.
JAMA 1998;279:1952-1953.
FULL TEXT  

The Randomized Controlled Trial Gets a Middle-aged Checkup
Jadad and Rennie
JAMA 1998;279:319-320.
FULL TEXT  

Evolution of treatment effects over time: Empirical insight from recursive cumulative metaanalyses
Ioannidis and Lau
Proc. Natl. Acad. Sci. USA 2001;98:831-836.
ABSTRACT | FULL TEXT